According to the CEO, phase III result should be out at any time now. Early Q2 2013, 8-10 weeks after early march.
Price Action suggests bad news coming.
If they miss the primary ep's on this, the stock could get cut in half. Be careful as their other pipeline products are moving more slowly than hoped (especially the comparative side effect profile to Biogen)